"Even at my physical just a month prior, the doctor hadn't noticed anything. I'm forever thankful that I mentioned it." ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...

Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...

This was the stock's second consecutive day of gains.

By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...

Request To Download Free Sample of This Strategic Report @- The expansion of US Kidney Cancer Therapeutics and Diagnostics Market is led by surge in kidney cancer cases, which is prompting demand for ...

The U.S. Justice Department said on Tuesday it entered an agreement to share $50 million in forfeited assets with Estonia in ...

Join Emmy-winning tech expert Jen Jolly for an exclusive first look at CES 2025's buzzworthy gadgets shaping the future of ...

Princeton molecular biologist Bonnie Bassler, emeritus professors Larry Martin Bartels and Ingrid Daubechies, and ...

Highlights,Bristol-Myers Squibb manages its debt effectively with solid earnings.,A substantial cash reserve supports the company's debt obligations.,Debt-to-EBITDA ratio and strong interest coverage ...

CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned ...